Mergers & Acquisitions
Greenhill's M&A practice includes some of the most experienced professionals in the industry. Drawing on that experience, we are active across the full range of M&A advisory roles:
Leveraging our independence and lack of conflicts, we have a strong track record in sell side advisory roles. Acting for target companies, special board committees or selling shareholders, we can operate at the heart of any process, assist in negotiations and give impartial and objective advice about the merits of bids received.
We have a strong record of successful buy side advisory assignments in relation to public or private target companies and are able to advise interested buyers on attractive targets through our global network of relationships.
Greenhill is well qualified to assist clients on merger transactions given the long experience of its partners and professionals, an assurance of total discretion and a lack of conflicting interests. Greenhill has a number of sizeable mergers in its list of completed transactions both in the US and internationally.
Various advisory work that we undertake does not fit a conventional ‘transaction’ definition. Examples include our work advising the Australian National Rugby League Commission on the sale of television broadcast rights and work for the global partnership of Arthur Andersen in the immediate aftermath of the cases that followed the collapse of Enron. We believe that Greenhill’s independence, experience, expertise and discretion positions us well for special advisory assignments.
Greenhill’s network of international offices and our ‘single Firm’ operating model allow us to offer clients a seamless cross-border advisory service with a truly global perspective.
Lion’s stake in Warrnambool Cheese and Butter Factory Company
Advised Lion (an Australian subsidiary of Kirin), on the sale of its strategic stake in Warrnambool Cheese and Butter Factory to Canadian-based Saputo, under its all cash takeover offer
Immunomedics, Inc. lead product candidate, IMMU-132
Advising Immunomedics, Inc. on the exclusive global licensing agreement with Seattle Genetics for the rights to develop, manufacture and commercialize sacituzumab govitecan (“IMMU-132”), an antibody-drug conjugate (ADC) targeted to TROP-2, which is expressed in several solid tumors, including cancers of the breast, lung and bladder
Booker Group plc
Advising Tesco plc, the UK’s leading retailer, on its merger with Booker Group plc, the UK’s leading food wholesaler, to create the UK’s leading food business
Advising LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on the sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V.
Subsidiaries and affiliates of Empresas Indumotora S.A.
Advised Inchcape PLC, a global leader in automotive retail and distribution, on the acquisition of a multi-country scale distribution business in Chile, Peru, Colombia, and Argentina for $290m (approximately £234m)